Digital tools aim to close learning gaps for young cancer survivors
NCT ID NCT05428176
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This study tests whether a special website and video coaching for parents can help children aged 6-12 who had leukemia or lymphoma improve their learning and school performance. Many children survive these cancers but may struggle with memory, attention, and thinking due to treatments. The program gives parents tips and support to help their child succeed in school.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
332 people
The number who actually took part.
- Started
-
Sep 2022
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
6 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Documented informed consent of the participant and/or legally authorized representative * Assent, when appropriate, will be obtained per institutional guidelines * Primary participating parent/caregiver is English- or Spanish-speaking (any race/ethnicity) * Child is aged 6-12 years (yr.) (for the website usability pre-study, child is age 8 - 12 yrs.) * Child understands English (but can be bilingual) * Child treated for acute leukemia (e.g., acute lymphoblastic leukemia, acute myelogenous leukemia) or lymphoblastic lymphoma * Child is in cancer remission and has completed cancer therapies, including maintenance treatment * Primary participating parent/caregiver has daily contact with the child * Child is enrolled in school Exclusion Criteria: * Recent or current participation in a behavioral intervention study with a similar focus * History of major psychiatric condition (e.g., psychosis) in parent or child * Severe neurodevelopmental disorder in the child (e.g., down syndrome, intellectual disability) * Child has previously used the IXL online learning program extensively and unwilling to regularly use it again * Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures * Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute leukemia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Childrens Hospital of Los Angeles
Los Angeles, California, 90027, United States
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
Rady Children's Hospital San Diego
San Diego, California, 92123, United States
-
University of Calif San Francisco
San Francisco, California, 94115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Why do some leukemia patients develop dangerous blood clots?
- Can a p53-Targeting drug boost chemotherapy in Hard-to-Treat blood cancers?
- Can an HDAC inhibitor wipe out residual leukemia cells?
- Can an experimental pill block a cancer-driving enzyme in hard-to-treat leukemia?
- Engineered immune cells aim to wipe out stubborn leukemia
- Two-Drug combo targets leukemia that outsmarted its first treatment